Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN EV / sales

EV / sales at other companies

AbbVie logo
AbbVieABBV
7.5×+1.0×
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
12.1×-0.9×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
4.3×-0.4×
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
3.7×+1.0×
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
3.3×+0.6×
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
3.8×-0.6×

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.58B+62.8%
Enterprise value$2.44B+62.3%
P/S3.3×+0.9×

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Calculated from Supernus Pharmaceuticals’s reported figures.

enterprise value/total revenue=3.6×

Based on the most recent quarter.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's EV / sales?
Supernus Pharmaceuticals (SUPN) reported EV / sales of 3.6× in Q1 2026.
How has Supernus Pharmaceuticals's EV / sales changed year-over-year?
Supernus Pharmaceuticals's EV / sales increased by 39.6% year-over-year, from 2.6× to 3.6×.
What is the long-term trend for Supernus Pharmaceuticals's EV / sales?
Over 5 years (2020 to 2025), Supernus Pharmaceuticals's EV / sales has grown at a 12.6% compound annual growth rate (CAGR), from 2.1× to 3.8×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.